Opioids and HIV
The purpose of this meeting is to update the San Francisco Bay Area (HIV research) community on the opioid epidemic and the current state of the science, especially as it pertains to HIV. We envision a broad scope covering national epidemiology and trends, an overview of the drug market (heroin versus fentanyl, an overview of clinical interventions available, a panel discussions on innovative uses of buprenorphine and safe consumption spaces, current research and interventions happening at the Veterans Affairs Medical Center, and policy and social justice developments.
Agenda
Understanding Changes in the U.S. 'Heroin' Market: Notes from the Field
The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Lessons Learned from Indiana 2015
Conditions of Possibility: Harm Reduction as a Pathway to Healing the Harms Caused by Racialized Drug Policies
Panel Discussion: Safe Consumption Spaces
Moving Beyond MEDD and Opioids to Address the Opioid Crisis
Unintended Consequences of the Opioid Epidemic on Clinician Practice
Chair
Image
Phillip Coffin, MD, MIA
Director, Center on Substance Use and Health, San Francisco Department of Public Health
Image
Monica Gandhi, MD, MPH
Director, UCSF-Bay Area CFAR
Planning Committee
Image
Milo Santos, PhD, MPH
Assistant Professor
Image
Laura Thomas, MPP, MPH
California Deputy State Director, Drug Policy Alliance
Contacts
Image
Lauren Sterling
Associate Director, UCSF-Bay Area CFAR
Image
César Cadabes
Community Engagement and Communications Program Analyst